✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Jenburkt Pharmaceuticals Ltd.

JENBURPH

Market Cap
₹577 Cr.
P/E
18.00

Jenburkt Pharmaceuticals Ltd.

  • Jenburkt Pharma
  • Prevest Denpro
  • Medicamen Biotech
FAQs on Jenburkt Pharmaceuticals Ltd. Shareprice

Jenburkt Pharma has given better returns compared to its competitors.
Jenburkt Pharma has grown at ~37.59% over the last 3yrs while peers have grown at a median rate of 20.43%

Yes, Jenburkt Pharma is expensive.
Latest PE of Jenburkt Pharma is 18.0, while 3 year average PE is 13.33.
Also latest EV/EBITDA of Jenburkt Pharma is 13.72 while 3yr average is 8.68.

View FAQ's On Business
Growth Table
  • Jenburkt Pharmaceuticals Ltd.
  • Prevest Denpro
  • Medicamen Biotech
Balance Sheet
  • Jenburkt Pharmaceuticals Ltd.
  • Prevest Denpro
  • Medicamen Biotech
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Jenburkt Pharmaceuticals Ltd.
  • Prevest Denpro
  • Medicamen Biotech
Cash Flow
  • Jenburkt Pharmaceuticals Ltd.
  • Prevest Denpro
  • Medicamen Biotech
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Jenburkt Pharmaceuticals Ltd.
  • Prevest Denpro
  • Medicamen Biotech
Quarterly Results
  • Jenburkt Pharmaceuticals Ltd.
  • Prevest Denpro
  • Medicamen Biotech
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Jenburkt Pharmaceuticals Ltd. Financials

Balance sheet of Jenburkt Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Jenburkt Pharma is increasing.
Latest net debt of Jenburkt Pharma is -₹47.25 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹158.32 Crs.

Yes, profit is increasing.
The profit of Jenburkt Pharma is ₹32.06 Crs for Mar 2025, ₹25.98 Crs for Mar 2024 and ₹24.61 Crs for Mar 2023

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Jenburkt Pharma latest dividend payout ratio is 24.78% and 3yr average dividend payout ratio is 25.53%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech